Abbott Laboratories vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| ABT | LLY | |
|---|---|---|
| Market Cap | $185.36 billion | $999.96 billion |
| Revenue (TTM) | $46.59 billion | $65.18 billion |
| Net Income (TTM) | $5.42 billion | $20.64 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ABT | LLY | |
|---|---|---|
| P/E Ratio | 34.67 | 48.86 |
| Price / Book | 3.58 | 37.68 |
| Price / Sales | 3.98 | 15.34 |
ABT leads on 3 of 3 valuation factors.
Profitability
| ABT | LLY | |
|---|---|---|
| Net Margin | 11.65% | 31.67% |
| Return on Equity | 10.48% | 77.78% |
LLY leads on 2 of 2 profitability factors.
Dividend
| ABT | LLY | |
|---|---|---|
| Dividend Yield | 2.35% | 0.62% |
| Payout Ratio | 81.55 | 30.15 |
ABT and LLY split the dividend factors evenly.
Risk & Sentiment
| ABT | LLY | |
|---|---|---|
| Short Interest | 0.57% | 1.29% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.